By ARTES Biotechnology…
To get in touch with ARTES Biotechnology GmbH, simply fill out the form below.
Subscribe to Supplier
New VLP Technology Patent Granted to ARTES Biotechnology
ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent in Australia for their VLP platform. The patent will further strengthen the Metavax® platform of the company. In combination with the expression platform Hansenula Metavax® is a unique tool for the development of affordable, safe and effective vaccines.
“Our intellectual property strategy is to provide multiple layers of protection for our technology platform portfolio. We believe that this new patent will have additional reinforcement to our existing patent estate and for our service we offer clients for vaccine development,” said Dr. Melanie Piontek, Business Development Director of ARTES.
About ARTES Biotechnology GmbH
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products.
For more information or to discuss the new VLP technology patent granted to ARTES Biotechnology please contact ARTES Biotechnology directly.